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Abstract
Background: Autoimmune diseases result from a breakdown in self-tolerance to autoantigens. Self-tolerance is induced and
sustained by central and peripheral mechanisms intended to deviate harmful immune responses and to maintain
homeostasis, where regulatory T cells play a crucial role. The use of self-antigens in the study and treatment of a range of
autoimmune diseases has been widely described; however, the mechanisms underlying the induced protection by these
means are unclear. This study shows that protection of experimental autoimmune disease induced by T cell self-epitopes in
a multimerized form (oligomers) is mediated by the induction of active suppression.
Principal Findings: The experimental autoimmune encephalomyelitis (EAE) animal model for multiple sclerosis was used to
study the mechanisms of protection induced by the treatment of oligomerized T cell epitope of myelin proteolipid protein
(PLP139–151). Disease protection attained by the administration of oligomers was shown to be antigen specific and effective
in both prevention and treatment of ongoing EAE. Oligomer mediated tolerance was actively transferred by cells from
treated mice into adoptive hosts. The induction of active suppression was correlated with the recruitment of cells in the
periphery associated with increased production of IL-10 and reduction of the pro-inflammatory cytokine TNF-a. The role of
suppressive cytokines was demonstrated by the reversion of oligomer-induced protection after in vivo blocking of either IL-
10 or TGF-b cytokines.
Conclusions: This study strongly supports an immunosuppressive role of repeat auto-antigens to control the development
of EAE with potential applications in vaccination and antigen specific treatment of autoimmune diseases.
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Introduction
Studies on the prevention and treatment of autoimmune
diseases have been focussed to the identification of antigens from
pathogens and autoantigens responsible for triggering autoim-
mune reactions. Under determined conditions, autoantigens able
to induce autoimmune disease can also suppress disease in a
number of experimental models [1,2]. Induction of antigen
specific tolerance based on the persistence of antigen can be
achieved after injection of high-dose antigen or repeated injections
of low dose soluble antigens [3,4,5]. T cell deletion, anergy
mechanisms and active suppression by regulatory cells constitute
essential factors in the maintenance of tolerance induced by these
means [3,6]. Active suppression represents one of the dominant
mechanisms in the control of autoreactivity characterized by
deviation of the immune response via the secretion of suppressive
cytokines [7,8].
The use of multivalent antigens represents an useful approach to
deal with the dose/concentration of the antigen required to induce
tolerance [9,10,11]. As an example, the synthetic repetitive
Copolymer-1 (Glatiramer Acetate), approved as a therapy for
relapsing remitting multiple sclerosis [12], contains sequences that
cross react with the myelin basic protein [13,14] and produce
immunomodulatory effects involving the induction of specific T
suppressor cells and bystander suppression mechanisms [15].
Despite several therapies for multiple sclerosis exist, their efficacy
is very limited and most of the drugs slow the progression of the
disease and reduce the number of relapses, however no complete
cure is achieved [16,17].
Our previous studies describe the role of repetitive oligomerized
peptides in the control of autoimmune diseases. It was shown that
a single low dose injection of oligomers, consisting of repeats of an
encephalitogenic T cell epitope from the proteolipid protein of
myelin, controlled the development of EAE in mice [9] and
oligomers of the neuritogenic epitope of myelin P2 protein
prevented the induction of experimental autoimmune neuritis
(EAN) [10]. Likewise, multimerized self epitopes in the type I
diabetes model demonstrated to provide protection against the
disease and it was correlated with the expansion of FoxP3+
regulatory cells [11].
Oligomers have proved to be effective in inducing strong
immune response because of their ability to crosslink efficiently
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class II molecules of the major histocompatibilty complex (MHC-
II) and to trigger signalling through the T cell receptor (TCR).
This might result in improved antigenicity due to the activation of
antigen presenting cells [18] and increased T cell proliferation
[19]. The mechanisms of action of oligomerized peptides in
suppressing the progression of autoimmune diseases are not
completely elucidated. Their suppressive effect has been explained
by the induction of anergy [20] or the expansion of regulatory cells
[11]. Some of the mechanisms underlying the tolerogenic capacity
of repeat antigens are described in this study. The ability of
oligomer peptides containing self-antigens to control the develop-
ment as well as the progression of ongoing experimental
autoimmune disease was correlated with the induction of
protective tolerance mainly mediated by suppressive cytokines.
Materials and Methods
Ethics Statement
The animals were maintained and handled according to the
Directive 86/609/ECC of the European Community Council and
to the institutional, state and federal guidelines. All animal
experiments were approved by the Landesamt fu¨r Arbeitsschutz,
Gesundheitsschutz und Technische Sicherheit (Berlin, Germany).
Animals were housed under standard conditions of 12-hour light/
dark cycle and given access to food and water ad libitum. During
periods of active paralysis, animals were provided gel pack and/or
moistened food on the cage floor. Animal suffering was reduced by
keeping the number of animals used to a minimum required for
the planned studies to give statistically significant data. Mice were
independently observed and monitored daily by both researchers
and animal care staff. Animals were euthanized when they met the
following humane endpoint criteria: i) animals with hind-limb and
fore-limb paralysis for more than three days without indication of
weight-gain and ii) any animal developing loss of bladder control
for more than three days. Animals were sacrificed once the
experiment was completed. In all cases, mice were humanely
sacrificed by injecting an overdose of an anaesthetic agent
(Ketamine/Rompun) solution.
Animals
10 to 12 weeks old, female SJL/J mice were used throughout the
experiments. Mice were purchased from Taconic Laboratories
(Rey, Denmark) or Charles River Laboratories (Sulzfeld, Ger-
many) and maintained under specific pathogen free conditions in
the animal facility at the Max Delbru¨ck Center.
Antigens
Proteolipid protein derived PLP139–151 (C140S) ((HSLGKWL
GHPDKF) later referred as PLP139–151 (Research Genetics EMC),
was synthesized by using standard solid phase F-moc chemistry.
All peptides were purified on a C4 -HPLC column (Vydac).
Oligomerized T cell epitopes, PLP139–151 16-mer (oligomer
containing 16 repeats of the encephalitogenic epitope derived
from the proteolipid protein PLP), were produced in Escherichia coli
bacteria using recombinant techniques as described [18]. In brief,
double-stranded oligonucleotide units encoding the T cell epitopes
of the PLP139–151 (C140S) oligomers were generated by annealing
two complementary strands of synthetic oligonucleotides (PLP139–
151 (C140S), +strand: 59-TCACTCTCTGGGTAAATGGCTG-
GGTCACCCGGATAAATTCGG, and - strand: 59-GAATTT-
ATCCGGGTGACCCAGCCATTTACCCAGAGAGTGACC).
They were linked to the nucleotide sequence of the S3 spacer
GGPGGGPGGGPGG by cloning the oligonucleotides into the
BsrDI site of a modified pCITE vector (Novagen), which
contained the DNA encoding the S3 spacer as described [9,18].
The HA107–119 4-mer consists of four covalently linked linear
HA107–119 peptides (SVSSFERFEIFPK), each linked by the S3
spacer. All oligomers were produced in E. coli using recombi-
nant techniques as previously described [18]. Endotoxin was
removed from the polypeptide oligomers by separation on a
reversed-phase C4-HPLC column (Vydac) and tested for
endotoxin with the colorimetric limulus test (Charles River
Laboratories).
Antibodies
For in vivo injection, mouse monoclonal antibodies (mAb), were
produced from hybridoma cell lines at the Max Delbru¨ck Center.
All hybridoma cell lines were kindly provided by Prof. Alexander
Scheffold, Deutsches Rheuma-Forschungszentrum Berlin, Ger-
many (DRFZ): anti-interleukin-10 (a-IL-10) (clone JES5-2A5)
[21], anti-IL-10 receptor (a-IL-10R) (clone 1B1.3a) [22], anti-
transforming growth factor beta (a-TGF-b) (clone 1D11) [23],
anti-interleukin-4 (a-IL4) (clone 11B11) [24], a-CD25 (clone
PC61) [25]. Rat IgG1 isotype (clone G1-113) was obtained from
Sigma. Briefly, antibodies were harvested from culture superna-
tants and precipitated with ammonium sulphate. Afterwards they
were purified over Protein G columns (Thermo scientific-Pierce,
Germany) and dialysed against phosphate buffered saline (PBS).
The protein concentration was determined by Bradford test and
the endotoxin level was measured with the limulus method.
Endotoxin levels were ,1 EU/mg protein. For flow cytometry
staining: a-CD4-PerCP-Cy5.5 (clone RM4-5) and anti-tumor
necrosis alpha (TNF- a) APC (clone XT22) were from BD
Pharmingen (San Diego, CA). a-CD154-PE (clone MR1) was
purchased from Miltenyi Biotech (Bergisch-Gladbach, Germany).
For separation of cell subpopulations: a-CD43-PE (clone L11) was
obtained from Miltenyi Biotec. a-CD45R/B220-PE (clone RA3-
6B2), a-CD25-FITC (clone PC61) and a-PE/FITC microbeads
were purchased from BD Pharmingen.
EAE induction and treatment
Mice were immunized subcutaneously at the base of the neck
and tail with 50 mg of PLP139–151 (C140S) peptide in incomplete
Freund’s adjuvant (IFA) (Sigma) containing 400 mg of Mycobacte-
rium tuberculosis H37Ra (Difco Laboratories- Detroit USA). One
day after priming, mice were injected intravenously with 200 ng of
Pertussis toxin (List Biological Laboratories, Inc UK) and scored
daily for clinical signs of EAE, according to a standard scale to
monitor the severity of EAE course [26]. The clinical score was
assessed as follows: 0, no clinical sign; 1, flaccid tail; 2, flaccid tail
and impaired righting reflex: 3, partial hind limb paralysis; 4, hind
and forelimb paralysis; 5, moribund. The effect of the PLP139–151
16-mer peptide in the progression of EAE was tested before and
after induction of the disease. Mice were vaccinated 7 days before
or were treated 7 days after EAE induction. The therapeutic effect
of oligomers was also tested after the appearance of the first
clinical signs of disease. In every case, 50 mg of PLP139–151 16-mer
peptide dissolved in PBS was administered intravenously. For
vaccination experiments, two routes of injection were tested;
intravenous injection and subcutaneous injection in IFA. To test
the antigen-specific effect of the oligomer, 50 mg of an unrelated
oligomer peptide HA107–119 4-mer was used for the EAE
treatment.
T cell proliferation assay
Spleen and lymph node cells from the EAE control group and
from oligomer treated mice were isolated on day 13 after disease
induction. Pooled spleen and lymph node cells were cultured at a
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density of 36105 cells per well in 96-well plates in RPMI-1640
medium (Invitrogen- Karlsruhe, Germany) supplemented with 5%
fetal calf serum (FCS) (Invitrogen). Cells were stimulated with
titrated amounts of PLP139–151 peptide and after 72 hours
incubation, the cultures were pulsed with 1 mCi (1 Ci = 37 GBq)
of 3H-thymidine (Amersham, Freiburg Germany) and incubated
for additional 16 hours. Cells were harvested for scintillation
counting in a Microplate Counter (Wallac 1420 Victor3TM-
Turku, Finland). Stimulation index was calculated by dividing the
PLP139–151 induced proliferation by proliferation in cultures with
medium only.
Cytokine production
To measure cytokine production, a single suspension of pooled
spleen and lymph node cells were used. For IL-10 detection,
46105 cells were stimulated with 10 mg/ml PLP139–151 monomer
peptide or PLP 16-mer in RPMI-1640 10% FCS for five days at
37uC. Cultures were re-stimulated with the antigen and irradiated
autologous antigen presenting cells for additional five days. IL-10
levels in the supernatants were quantified by ELISA using mouse-
IL-10 (OptEIA TM, BD Biosciences). Briefly, plates were coated
with IL-10 capture antibody in carbonate buffer and blocked with
a PBS-10% FCS for 1 hour at room temperature. Supernatants
were added to the wells and incubated for 1 hour at room
temperature. Plates were further incubated with biotinylated anti-
mouse IL-10 and avidin-horseradish peroxidase conjugate and
developed by the addition of TMB substrate solution (KPL
Gaithersburg, Maryland USA). IL-10 levels in culture superna-
tants were determined by interpolation from the IL-10 standard
curve. Reactions were measured at 450 nm absorbance in an
ELISA reader (VictoR 3V TM Perkin Elmer- Germany).
For TNF-a detection, 56105 cells were isolated from oligomer
treated (13 days after EAE induction) and untreated mice. Cells
were activated for 6 hours with 20 mg/ml PLP139–151 peptide and
4 mg/ml a-CD28 (clone 37.51) [27] produced at the Max
Delbru¨ck Center (the hybridoma cell line was provided by Prof.
Alexander Scheffold) To block cytokine secretion, 5 mg/ml
Brefeldin A (Sigma) was added for the last four hours of
stimulation. Cells were resuspended in PBS-2% FCS/EDTA
2 mM (MACS buffer) and stained for surface CD4, followed by
fixation and permeabilization for 30 minutes at 4uC using the
Cytofix-Cytoperm solution (BD Biosciences Pharmingen). For
detection of cytokines in antigen-specifically activated T cells,
combined intracellular CD154 and TNF-a staining was performed
[28]. The frequency of CD154+ TNF-a+ double positive cells in
the total CD4+ lymphocytes was determined and analysed on a
LSR II cytometer with a BD Bioscience FACSDivaTM software.
Adoptive cells transfer
Spleen cells and lymph node from oligomer treated and non-
treated mice were collected 13 days after EAE induction. Cell
suspensions were prepared by mincing tissue fragments in medium
and filtered through a nylon mesh (BD-Falcon). Erythrocytes were
lysed with a hypotonic ammonium chloride solution (NH4Cl
0.83%) for 3 minutes at 37uC. Total lymphoid cells and different
cell subpopulations were assessed for the ability to confer
protection to recipient mice in adoptive transfer experiments.
Subpopulations of B220+, CD4+CD25+ and CD4+CD252 cells
were separated by immunomagnetic cell sorting. Briefly, 20 ml of
a-CD43 and 10 ml of microbeads were added per 16107 total cells
and incubated for 20 min at 4uC. Untouched B cells were
collected in the column effluent using MidiMACS LD columns
(Miltenyi Biotech). Positive and negative selection was used to
isolate CD4+CD25+ and CD4+CD252 cells. In brief, B cells were
depleted using a-CD45R/B220 and microbeads. The fraction of
B2202 cells was incubated with a-CD25 and microbeads and after
magnetic separation, CD4+CD25+ cells were enriched using
MidiMACS LScolumns (Miltenyi Biotech). The negative fraction
was enriched in CD4+CD252. Purity of isolated cell populations
was greater than 95% as determined by flow cytometry. 56106
total lymphoid cells or 56106 cells from each subpopulation were
resuspended in PBS 1% FCS and intravenously transferred to
recipient mice, one day before the EAE induction.
In vivo neutralization of cytokines
mAb a-IL-10R was used to block IL-10 signalling. mAbs a-IL-
10, a-TGF-b, a-IL-4 and IgG1 isotype control, were used for in
vivo neutralization of cytokines. PLP139–151 16-mer treated mice
were injected intraperitoneally on days 7, 9, 11 and 13 after
disease induction with 0.5 mg of the corresponding antibody. The
effect of cytokine blockade on the clinical course of EAE was
monitored daily.
Statistical analysis
For comparison of clinical EAE scores, significance between the
groups was determined by nonparametric Mann-Whitney U test.
Data represent the mean 6SEM ***P,0.001, **P,0.01,
*P,0.05. Statistical differences in proliferation and cytokine
responses were evaluated using Student’s t test. P values
*P,0.05 were considered significant. Sigmaplot software (San
Jose).
Results
Prevention of EAE induced by administration of PLP139–
151 16-mer and antigen specificity
We had shown earlier the therapeutic efficacy of multimerized
epitopes in the treatment of autoimmune diseases [9,10,11]. In the
present study, we tested whether the oligomers were effective
before disease induction or when administered after the onset of
clinical signs of EAE. We used the susceptible SJL/J (H-2s) strain
of mice to evaluate the effect of the epitope oligomer on the
evolution of EAE. Upon immunization with the PLP139–151
epitope, mice developed clinical signs of EAE around day 10,
reaching the peak of severity at about 15 days post-induction. The
administration of the oligomer PLP139–151 16-mer after or prior
EAE induction inhibited the evolution of disease almost
completely (Fig. 1A and B). At the peak of clinical disease (day
13), treated and vaccinated mice had a significant decrease in the
severity of the disease. Oligomer treated mice showed a mean
clinical score of 0.260.2, compared with a score of 2.660.2 in the
control untreated group, p = 0.008 (Fig. 1A). Likewise, epitope-
oligomer vaccination of either subcutaneous or intravenous
injection routs prevented the EAE development. There was a
significant decrease in the severity of the disease in both vaccinated
groups, with a mean clinical score of 0.560.3 for subcutaneous
and 0 for intravenous vaccination compared with a score of
2.860.3 in the control group; p= 0.0096 and p= 0.008 respec-
tively (Fig. 1B). To determine the therapeutic effect of the epitope
oligomers during disease, mice were given individually PLP139–151
16-mer after the onset of the disease. Figure 1C, shows the
effectiveness of the treatment even if delayed until the appearance
of the first disease signs. Treated mice showed a mean clinical
score of 2.360.2 at the peak of disease (day 17) compared with
0.1360.1 in untreated mice, p = 0.0009.
To establish that the protection induced by oligomer treatment
was antigen specific, the effect on the suppression of the disease
was tested by the use of irrelevant oligomers (4-mers) of an epitope
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derived from the influenza virus hemagglutinin protein (HA107–
119) containing the same spacer sequence linked to the NH2-
terminal side (S3 spacer) as the oligomerized encephalitogenic
antigen PLP139–151 16-mer. The results show that no protection
was achieved in mice treated with the HA107–119 4-mer, as they
exhibited a mean maximal clinical score of 2.260.3, comparable
with 1.860.4 in untreated mice with disease incidence of 100% for
both groups. On the other hand, mice treated with PLP139–151 16-
mer were completely protected against the disease (Fig. 2). The
plot shows a significant difference (p = 0.008) on the protection
conferred by the oligomer containing the specific antigen
compared to the unrelated oligomer.
Ex vivo proliferation assay
The effectiveness of antigen specific therapies for autoimmune
diseases has been correlated with the lack of antigen T cell
response [29]. The ex vivo capacity of cells from oligomer treated
mice to respond against the cognate antigen was tested. Cells from
oligomer treated and untreated mice were isolated on day 13 post-
immunization and were challenged in vitro with different dosages of
PLP139–151 peptide. Antigen specific response was not completely
inhibited in oligomer treated mice, although a substantial
reduction in proliferation was observed (Fig. 3A). On the other
Figure 1. Protection against EAE development after adminis-
tration of PLP139–151 16-mer. (A) EAE was induced in SJL/J mice with
50 mg of the encephalitogenic PLP139–151 peptide emulsified in
complete Freund’s adjuvant containing Mycobacterium tuberculosis.
Mice were untreated or treated intravenously with 50 mg of the PLP139–
151 16-mer on day 7 after disease induction as represented by the arrow.
(B) Mice were vaccinated subcutaneously or intravenously with 50 mg of
PLP139–151 16-mer. Vaccination was performed 7 days before EAE
induction as indicated by the arrow. Subcutaneous injection was given
in incomplete adjuvant and for the intravenous injection the oligomer
was dissolved in PBS. (C) Mice (n = 8) were treated individually once the
first clinical signs of EAE appeared. 50 mg of the PLP139–151 16-mer was
given intravenously in diseased mice. The plots show the mean 6SEM
daily clinical score. Statistical significance between groups was
determined was determined by Mann-Whitney U test. ***P,0.001,
**P,0.01 and *P,0.05 compared with respective control group.
doi:10.1371/journal.pone.0064888.g001
Figure 2. Antigen specificity is required for the protection
induced by PLP139–151 16-mer. EAE was induced in SJL/J mice with
the PLP139–151 peptide in complete adjuvant. On day 7 after disease
induction, mice were treated intravenously with PLP139–151 16-mer or
with an unrelated oligomer containing an epitope derived of the
influenza virus hemagglutinin protein (HA107–119 4-mer) as indicated by
the arrow. Mice were monitored daily and the average 6SEM of the
clinical score of five mice per group was calculated. Statistical significant
difference between the PLP139–151 16-mer and HA107–119 4-mer treated
groups was observed (**P,0.01).
doi:10.1371/journal.pone.0064888.g002
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hand, significant higher levels of antibodies to the specific peptide
were detected in serum of oligomer treated mice compared to the
untreated animals (Figure S1).
Cytokine production
To investigate whether the PLP139–151 16-mer treatment
regulates the secretion of pro-inflammatory and anti-inflammatory
cytokines, cells from lymphoid tissues of treated and untreated
mice were isolated on day 13 post-immunization (6 days after
treatment) and the production of TNF-a and IL-10 was measured
upon ex-vivo stimulation. Intracellular expression of TNF-a was
quantified by flow cytometry. Co-expression of CD154 was used
as a marker to identify activated antigen specific cytokine-secreting
CD4+ cells [28]. Figure 3B, indicates the percentage of positive
cells for TNF-a and CD154 expression in CD4+ cells after antigen
stimulation. Stimulation with PLP139–151 peptide and a-CD28
revealed increased percentages of TNF-a expressing cells in
untreated mice in comparison with treated mice, being 0.16% and
0.09% respectively. Similar results were observed on days 2 and 4
after oligomer treatment (data not shown). Significance differences
were *p,0.05 in both CD154 and TNF-a expression.
The anti-inflammatory cytokine IL-10 has been showed to play
a pivotal role in tolerance induction; particularly in the EAE
model, it has been characterised as a key cytokine in the
suppression of the disease [30]. It was of interest to look whether
PLP139–151 16-mer treatment could modulate the IL-10 produc-
tion in comparison to untreated mice. As IL-10 is difficult to detect
by intracellular staining methods due to its rapid secretion and
short half-life [31,32], in this study the IL-10 secretion was
quantified by ELISA using short-term cell cultures generated after
repeated antigen specific stimulation. Combinations of monomeric
PLP139–151 and oligomer 16-mer peptide for cell stimulation were
compared in their ability to modulate the IL-10 production
(Fig. 3C).
Results demonstrated enhanced IL-10 production in cultured
cells from oligomer treated mice and reduced IL-10 secretion in
cells from untreated mice, regardless of the peptide used for the
stimulation. In particular, monomer-oligomer stimulation resulted
in about 6-fold increase in IL-10 production in treated mice.
Similar results were found when IL-10 levels were measured in
purified B cells from treated and untreated mice (data not shown).
Figure 3. Antigen specific stimulation and cytokine production
of cells from PLP139–151 16-mer treated mice. (A) Lymphoid tissue
cells from oligomer treated mice were isolated on day 13 post-
immunization and stimulated with titrated amounts of PLP139–151
peptide. 36105 cells were incubated for 72 hours and the T cell
response was measured by 3H-thymidine incorporation. Stimulation
index was calculated as the ratio of mean counts per minute (cpm) from
quadruplicate mice to the mean background cpm. An index .2 was
considered positive. **P,0.01 and *P,0.05 compared to untreated
controls by Student’s t test analysis. (B) Ex vivo TNF-a secretion by cells
from PLP139–151 16-mer treated and untreated mice was measured. Cells
were isolated on day 6 after oligomer treatment and stimulated with
20 mg/ml PLP139–151 peptide and 4 mg/ml a-CD28 for 6 h. The
intracellular TNF-a cytokine was quantified on CD4+CD154+ activated
cells by FACS analysis. *P,0.05 compared to untreated controls by
Student’s t test analysis. (C) To measure IL-10 secretion, lymphoid tissue
cells from PLP139–151 16-mer treated mice and untreated mice were
stimulated on days 0 and 5 with different combinations of the PLP139–
151 peptide (monomer) or the PLP139–151 16-mer (oligomer). Stimulation
was performed with: (a) monomer-monomer, (b) monomer-oligomer,
(c) oligomer-monomer and (d) oligomer-oligomer peptides. After 10
days in culture, supernatants were collected and the production of IL-10
was measured by ELISA. Results are expressed as the mean cytokine
concentration (pg/ml). **P,0.01 compared to untreated controls by
Student’s t test analysis.
doi:10.1371/journal.pone.0064888.g003
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Adoptive cell transfer
T and B lymphocytes with regulatory functions have shown to
play an important role in the maintenance of peripheral tolerance
in autoimmune diseases [33,34]. The potential suppressive
function of cells from oligomer treated mice was tested by
adoptive transfer of lymphoid cells and cell populations into EAE-
induced SJL/J recipient mice. Modulation of disease severity was
assessed by the transfer of purified CD4+CD25+, CD4+CD252
and B cells from oligomer treated and untreated mice.
Protection induced in oligomer treated mice was actively
transferred. Mice receiving total spleen cells from the treated
group had decreased clinical signs of disease, displaying a mean
maximal score of 2.561.2. In contrast, mice that received CFA-
primed cells developed a normal form of EAE (mean maximal
score of 4.260.7, p= 0.2) with a relapsing phase at a later time
point of the disease course (Table 1). In line with this result,
distinct cell subpopulations derived from oligomer treated animals
were also effective in reducing the severity of EAE as evidenced by
reduction of clinical score and disease incidence. Transfer of
CD4+CD25+, CD4+CD252 or B cells from treated mice was
correlated with reduced clinical scores, contrary to the transfer of
cells from untreated mice, which failed to transfer suppression
(Table 1). In particular, mice receiving CD4+CD25+ or B cells
from oligomer treated mice manifested reduced severity of
paralysis showing a mean maximal clinical score of 1.760.6 and
1.460.6 respectively in comparison with 3.061.2 (p= 0.4) and
3.060.3 (p= 0.056) in their respective control group. Significant
differences between the EAE control group and animals trans-
ferred with total cells or different cell populations from treated
mice were found at the peak of clinical disease (data not shown).
Neutralization of anti-inflammatory cytokines influence
the suppressive effect induced by oligomer treatment
Previous studies have shown that IL-10 and TGF-b have anti-
inflammatory and protective effects in a variety of autoimmune
diseases [35,36,37]. To test whether IL-10 in vitro production
observed in treated mice directly correlates to the protective effect
provided by the oligomer treatment in vivo, mice were systemically
administered a-IL-10 or a-IL-10 receptor (IL-10R) monoclonal
antibodies. The results show that inhibition of IL-10 reverses
oligomer-mediated protection of EAE (Fig. 4).
In vivo neutralization of IL-10 with either a-IL-10 or a-IL-10R
significantly affected the immunomodulatory function of the
treatment with PLP139–151 16-mer. More effective blockage of
IL-10 was achieved with a-IL-10R antibody than with a-IL-10, as
has been reported before [38]. Analysis of the clinical EAE scores
shows that oligomer treated mice displayed a peak of relapsing
following administration of a-IL-10R antibody on day 15,
reaching similar clinical scores as the untreated animals, mean
score of 2.060.3 and 2.260.2 respectively. In contrast, oligomer
treated mice that did not receive IL-10 blocking antibodies had
significantly decreased EAE signs (mean score of 0.660.2)
compared to treated animals injected with a-IL-10R (mean
clinical score 2.060.3, p = 0.016) or a-IL-10 (mean clinical score
1.660.2, p = 0.056) (Fig. 4). Injection of isotype control antibody
had no effect on the protective effect induced by the treatment
(Figure S2).
To identify the role of other suppressive cytokines in the
PLP139–151 16-mer induced tolerance to EAE, neutralization of
TGF-b was carried out. Administration of anti-TGF-b completely
impairs the ability of the PLP139–151 16-mer to inhibit the EAE
development. On day 13, all oligomer treated mice receiving
TGF-b blocking antibodies presented EAE signs and about day 18
they reached the same score as the untreated mice (mean maximal
score of 260.4), whereas complete protection was achieved in
oligomer treated animals (p = 0.008).
(Fig. 5). Conversely, neutralization of IL-4 did not affect the
inhibition of disease development in treated mice. Thus, neutral-
ization of IL-10 and TGF-b was sufficient to abrogate EAE
protection in treated mice, suggesting that oligomers play an
important role in the modulation of the immune response.
Discussion
In this study we show that vaccination and therapeutic
treatment with PLP139–151 16-mer prevented efficiently the
development of EAE. Importantly, the administration of oligomers
after the appearance of the first clinical signs of EAE could control
the evolution of the disease. The broaden effectiveness of
oligomerized peptides to induce tolerance has been described in
the context of high-zone tolerance [18] as a threshold in the
number of antigen recognition sites associated by repeating
antigenic determinants [39,40].
Table 1. Adoptive transfer of cells from PLP139–151 16-mer treated mice.
Transfer Donor No. EAE
Mean Group
Score ±SEMa
Mean EAE Score
±SEMb
Mean Day of Onset
±SEM
B220+ cells Oligomer treated mice 3/5 1.460.6 2.360.3 13.361.4
Untreated mice 4/5 2.860.8 3.560.5 12.260.6
EAE Control – No transfer 5/5 3.060.3 3.060.3 12.261.0
CD4+CD25+ Oligomer treated mice 3/4 1.760.6 2.360.3 8.360.3
CD4+CD252 Oligomer treated mice 4/4 2.560.3 2.560.3 13.562.6
EAE Control – No transfer 3/4 3.061.2 4.061.0 13.761.2
Spleen cells Oligomer treated mice 3/4 2.561.2 3.361.2 10.061.0
CFA primed mice 4/4 4.260.7 4.260.7 11.760.7
Subpopulations of B220+, CD4+CD25+ and CD4+CD252 cells were purified from CFA primed mice and oligomer treated and untreated SJL/J mice. Cell separation was
performed by immunomagnetic sorting. 56106 total spleen cells or 56106 cells from each subpopulation were resuspended in PBS 1% FCS and intravenously injected
into recipient mice, one day before the EAE induction. The effect of adoptive cell transfer to modulate the evolution of EAE was assessed. Animals were monitored daily
for development of EAE.
aMean 6 SEM of maximum clinical score of EAE from all animals in the group.
bMean 6 SEM of maximum clinical score from animals exhibiting EAE within a group.
doi:10.1371/journal.pone.0064888.t001
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The protection induced by oligomer T cell epitope PLP139–151
was dependent of antigen specificity. An unrelated oligomer
HA107–119 4-mer, containing the epitope derived from the
influenza virus, which also contains the same spacer sequence as
the PLP139–151 16-mer between repeats, did not have effect in the
protection of EAE. Antigen-specific therapies that involve T cell
recognition for the regulation of autoimmune response represent
one of the most reliable approaches to treat or prevent
autoimmune disorders [41,42].
In our previous studies, the histopathological analysis of the
brain and spinal cord from oligomer treated mice showed no
inflammation or demyelination in contrast to control mice [9]. In
line with these observations, here we found significantly less
infiltration of cells in the CNS of treated animals and higher
numbers of cells were recruited in spleen and lymph nodes.
Throughout the experiments performed, increased size of spleen
and lymph nodes was observed in treated animals (data not
shown). The immunological study of cells from oligomer treated
and untreated mice was carried out in cells from peripheral tissues.
The phenotypic characteristics of lymphocyte populations isolated
from oligomer treated mice did not reveal considerable differences
in the expression of markers associated with regulatory functions,
co-stimulation, migration markers or activation molecules com-
pared with untreated animals (data not shown).
In addition, oligomer treatment did not induce antigen-specific
unresponsiveness. Although to a lesser extend, cells from treated
mice proliferated after in vitro activation with the cognate peptide.
Similar findings have been documented in other experimental
models for the treatment of EAE, where normal proliferation
against self antigens is achieved in tolerized animals with high
doses of antigen, DNA encoding self peptides or recombinant
TCR ligands [43,44]. The analysis of the humoral response reveals
that shortly following the treatment with PLP139–151 16-mer, high
levels of antigen specific antibodies were produced, although there
were not significant differences in the concentration of IgG
subclasses. In contrast, untreated mice only produced low amounts
of the different isotypes (Figure S1).
Adoptive transfer of serum from treated mice had no significant
effect on the evolution of EAE (data not shown). A feature of
multivalent antigens is the ability to induce B cells for the
production of antibodies with the help of specific CD4+ cells
[45,46]. The role of these antibodies and the formation of immune
complexes in relation with inhibitory Fc receptors is a subject for
future research.
Figure 4. Effect of in vivo neutralization of IL-10 on the PLP139–151 16-mer treatment. Oligomer treated mice were intraperitoneally injected
with 0.5 mg of a-IL-10 or a-IL-10R (anti-IL-10 receptor). Injections were performed four times from the day of the treatment, every two days as
indicated by the arrows. Untreated mice were used as control. Mice were monitored daily and the mean clinical score 6SEM was analyzed. These
results are representative of two independent experiments. Statistical significance, **P,0.01 and *P,0.05 compared to PLP139–151 16-mer treated
mice that were not administered anti-cytokine blocking antibodies. No effect was observed in oligomer treated mice given isotype control IgG1
antibody (Figure S2).
doi:10.1371/journal.pone.0064888.g004
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After antigen stimulation in vitro, cells derived from oligomer
treated mice showed significant reduction in TNF-a secretion and
enhanced IL-10 production in contrast to untreated mice. This
suggests a role of oligomerized epitopes in the modulation of the
inflammatory response by inducing antigen-specific cells to the
production of suppressive cytokines. Interestingly, total spleen
cells, CD4+CD25+ and B cells from oligomer treated mice actively
transferred protection to recipient mice. Mice transferred with
CD4+CD25+ cells from oligomer treated donors had earlier onset
of disease, possibly due to the presence of autoreactive effector
CD25+ cells in the CD25+ regulatory T cell pool. However, these
animals recovered in a short time showing significant decrease in
the severity of EAE. CD252 cells were less effective in the
suppression of disease. The role of CD4+CD25+ cells in the
regulation of autoimmune diseases has been widely described [47].
In future experiments, the DEREG mouse model in which all
Foxp3+ cells are depleted would be useful to explore the role of T
regulatory cells in the oligomer-induced protection [48]. Likewise,
adoptive transfer of B cells from oligomer treated mice amelio-
rated the severity of disease in recipient mice. These cells secrete
increased amounts of IL-10 after in vitro activation with a-CD40
compared to B cells from the control group (data not shown). This
is in agreement with previous reports, which demonstrate that the
regulatory role of B cells is mainly mediated by IL-10. Some of
these studies indicate that treatment with B cells producing IL-10
can modulate the course of arthritis, inflammatory bowel disease
and EAE [34,49,50]. In vivo IL-10 production is one of the possible
mechanisms by which B cells from oligomer treated animals
transfer suppression of EAE.
The immunomodulatory role of suppressive cytokines such as
IL-10 and TGF-b was found to be crucial for the EAE protection
induced by repetitive oligomers. In vivo neutralization of IL-10 or
TGF-b reversed the protective effect induced by PLP139–151 16-
mer treatment. IL-10 and TGF-b are key molecules in the
maintenance of peripheral tolerance. According to a number of
studies, IL-10 exerts down-modulatory functions that may
diminish autoimmune pathologies. IL-10-deficient mice have
shown to develop more severe EAE than wild-type mice, and
some IL-10 promoter polymorphisms are associated with progres-
sion of multiple sclerosis [36,51]. Additionally, IL-10 has also been
implicated in various immunotherapeutic models in which its
administration can inhibit the development of EAE [52,53]. In the
same way, TGF-b also plays an important role in T cell
homeostasis and prevention of inflammatory autoimmunity [54].
TGF-b deficient mice develop systemic inflammation and
abrogation of TGF-b signalling results in spontaneous T cell
differentiation and autoimmune disease [55]. The involvement of
different subpopulations of T regulatory cells (Tr1 cells) in the
production of IL-10 and TGF-b and/or Th3 cells that secrete
TGF-b [56,57] during the oligomer treatment, is an interesting
topic for future research.
This study shows that the protection achieved by the oligomer
treatment is mainly mediated by the induction of active
suppression, which involves the expansion of antigen-specific cells
that mainly produce anti-inflammatory cytokines. We added
evidence that active suppression underlies the therapeutic efficacy
of oligomers in EAE, suggesting that the use of oligomerized-self
epitopes as an antigen-specific therapy constitutes an alternative
approach in the modulation of the immune response in
autoimmune diseases.
Supporting Information
Figure S1 Determination of antibody response to
PLP139–151 in oligomer treated mice. Mice were treated
intravenously with 50 mg of the PLP139–151 16-mer on day 7 after
EAE induction. PLP139–151-specific antibody determination was
tested two weeks after oligomer treatment. Levels of IgG isotypes
in serum samples from treated and untreated mice were
determined by ELISA. Higher levels of the different isotypes of
antibodies specific to the cognate antigen were observed in
oligomer treated mice in comparison to the untreated ones.
(TIF)
Figure S2 Effect of in vivo neutralization of IL-10R on
the PLP139–151 16-mer treatment. Oligomer treated mice
were intraperitoneally injected with 0.5 mg of a-IL-10R (anti-IL-
10 receptor) or isotype control IgG1 antibody. Injections were
performed four times from the day of the treatment, every two
days. Oligomer treated mice injected with a-IL-10R developed
EAE similar to untreated mice, in contrast to oligomer treated
animals injected with the isotype control antibody, which
developed very mild disease. Statistical significance between these
two groups was observed at the peak of clinical disease (day 14)
*P,0.05.
(TIF)
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Figure 5. Effect of in vivo neutralization of TGF-b on the PLP139–
151 16-mer treatment. Oligomer treated mice were intraperitoneally
injected with 0.5 mg of a-TGF-b or a-IL4. Injections were performed
four times from the day of oligomer treatment every two days as
indicated by the arrows. Clinical signs of EAE were scored daily. Data
represent the mean 6SEM of the clinical score. **P,0.01 compared to
PLP139–151 16-mer treated mice that were not administered anti-
cytokine blocking antibodies. No effect was observed in oligomer
treated mice injected with isotype control IgG1 antibody (Figure S2).
doi:10.1371/journal.pone.0064888.g005
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